A New Radiopharmaceutical 225Ac-DOTA-IBA in the Treatment of a Case of Bone Metastases.
Sign Up to like & getrecommendations! Published in 2023 at "Clinical nuclear medicine"
DOI: 10.1097/rlu.0000000000004688
Abstract: ABSTRACT α-Emitter 225Ac has been considered a candidate for targeted α-therapy. DOTA-IBA is new a precursor targeting bone metastasis. It can be used for radionuclide labeling with 225Ac. We present a case with refractory bone… read more here.
Keywords: bone; 225ac dota; case; new radiopharmaceutical ... See more keywords